Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Wei Zhang 2 Articles
CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer
Guolin Zhang, Xin Luo, Wei Zhang, Engeng Chen, Jianbin Xu, Fei Wang, Gaoyang Cao, Zhenyu Ju, Dongai Jin, Xuefeng Huang, Wei Zhou, Zhangfa Song
Cancer Res Treat. 2020;52(2):622-633.   Published online December 31, 2019
DOI: https://doi.org/10.4143/crt.2019.593
AbstractAbstract PDFPubReaderePub
Purpose
5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance. Emerging observations revealed the important role of chemokine (C-X-C motif) ligand 13 (CXCL-13) in tumor microenvironment and its relationship with prognosis in patients with colorectal cancer. This study is designed to reveal the important role of CXCL-13 in causing colorectal cancer resistance to 5-Fu.
Materials and Methods
CXCL-13 levels of patient's serum or cell culture supernatants were measured separately by enzyme-linked immunosorbent assay. In cell assays, cell viability is detected by Cell Counting Kit-8. Therefore, the recombinant human CXCL-13 was used to simulate its high expression in cells while its antibody and siRNA were used to reduce CXCL-13 expression in cells.
Results
In this study, we demonstrated that CXCL-13 is associated with 5-Fu resistance by culture medium exchange experiments and cytokine arrays of colorectal cancer resistant and nonresistant cells. Clinical studies showed that CXCL-13 is highly expressed in the serum of 5-Fu–resistant patients. High levels of serum CXCL-13 also predict a worse clinical outcome. The addition of recombinant CXCL-13 cytokine resulted in 5-Fu resistance, while its antibody overcame 5-Fu resistance, and knockdown of CXCL-13 expression by siRNA also reduced 5-Fu resistance, which can be saved by added recombination CXCL-13.
Conclusion
These results not only identify a CXCL-13 mediated 5-Fu resistance mechanism but also provide a novel target for 5-Fu–resistant colorectal cancer in prevention and treatment strategies.

Citations

Citations to this article as recorded by  
  • Mechanism of 5-fluorouracil induced resistance and role of piperine and curcumin as chemo-sensitizers in colon cancer
    Dorothy Bhattacharjya, Nageswaran Sivalingam
    Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(11): 8445.     CrossRef
  • The combination of SHP099 inhibits the malignant biological behavior of L-OHP/5-FU-resistant colorectal cancer cells by regulating energy metabolism reprogramming
    Meilian Wang, Kun Yu, Wen Fu, Lihong Yang
    Biochemical and Biophysical Research Communications.2024; 728: 150262.     CrossRef
  • Serum CXCL13 as a Novel Biomarker in Oral Squamous Cell Carcinoma
    Shin Tojo, Koh‐ichi Nakashiro, Nobuyuki Kuribayashi, Daisuke Uchida
    Cancer Medicine.2024;[Epub]     CrossRef
  • The potential of kaempferol in digestive system tumors: recent advances and mechanistic insights
    Xunxing Hao, Meng Ding, Chenyu Chi, Xiaodong Xu, Xiaoyu Zhang, Mingzhe Hu
    Discover Oncology.2024;[Epub]     CrossRef
  • Identification of a tissue resident memory CD8 T cell-related risk score signature for colorectal cancer, the association with TME landscapes and therapeutic responses
    Jiazheng Li, Chao Yang, Yongbin Zheng
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Prognostic Significance of the CXCLs and Its Impact on the Immune Microenvironment in Ovarian Cancer
    Cairu Gu, Xifeng Xiong, Wei Liu, Elisa Belluzzi
    Disease Markers.2023; 2023: 1.     CrossRef
  • TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer
    Yaoqing Li, Chuchu Xu, Renjun Zhu, Liyijing Shen, Gengyuan Hu, Kelong Tao, Feng Tao, Zengxin Lu, Guolin Zhang
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7235.     CrossRef
  • Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
    Katharine Yu, Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay, James E. Korkola, Gillian L. Hirst, Smita Asare, Angela DeMichele, Nola Hylton, Douglas Yee, Laura Esserman, Laura van ‘t Veer, Marina Sirota
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Host Transcriptional Regulatory Genes and Microbiome Networks Crosstalk through Immune Receptors Establishing Normal and Tumor Multiomics Metafirm of the Oral-Gut-Lung Axis
    Beatriz Andrea Otálora-Otálora, Juan Javier López-Rivera, Claudia Aristizábal-Guzmán, Mario Arturo Isaza-Ruget, Carlos Arturo Álvarez-Moreno
    International Journal of Molecular Sciences.2023; 24(23): 16638.     CrossRef
  • Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experiments
    Hu Chen, Junsei Sameshima, Shiho Yokomizo, Tomoki Sueyoshi, Haruki Nagano, Yuka Miyahara, Taiki Sakamoto, Shinsuke Fujii, Tamotsu Kiyoshima, Thomas Guy, Seiji Nakamura, Masafumi Moriyama, Naoki Kaneko, Shintaro Kawano
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Identification of Key Gene Targets for Sensitizing Colorectal Cancer to Chemoradiation: an Integrative Network Analysis on Multiple Transcriptomics Data
    Hamed Manoochehri, Akram Jalali, Hamid Tanzadehpanah, Amir Taherkhani, Massoud Saidijam
    Journal of Gastrointestinal Cancer.2022; 53(3): 649.     CrossRef
  • Exosomes-mediated tumor treatment: One body plays multiple roles
    Na Xu, Ranran Guo, Xiaotong Yang, Ning Li, Jia Yu, Peng Zhang
    Asian Journal of Pharmaceutical Sciences.2022; 17(3): 385.     CrossRef
  • Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
    Ching-Hung Hsieh, Cheng-Zhe Jian, Liang-In Lin, Guan-Sian Low, Ping-Yun Ou, Chiun Hsu, Da-Liang Ou
    Cancers.2022; 14(2): 294.     CrossRef
  • Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma
    Xiaonan Zhou, Shizhu Guo, Yonghong Shi
    Scientific Reports.2022;[Epub]     CrossRef
  • Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis
    Haili Wu, Jin’e Du, Chenglu Li, Hanqing Li, Huiqin Guo, Zhuoyu Li
    International Journal of Molecular Sciences.2022; 23(7): 3544.     CrossRef
  • Chemokines and chemokine receptors in colorectal cancer; multifarious roles and clinical impact
    Maria Braoudaki, Mohammed Saqif Ahmad, Denis Mustafov, Sara Seriah, Mohammad Naseem Siddiqui, Shoib Sarwar Siddiqui
    Seminars in Cancer Biology.2022; 86: 436.     CrossRef
  • Bioinformatics Analysis of Prognostic Significance and Immune Characteristics of CXC Chemokine Family in Patients with Lung Adenocarcinoma
    Dachen Bian, Yanhua Chen, Ahmed Faeq Hussein
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer
    Qian Zou, Xue Lei, Aijing Xu, Ziqi Li, Qinglian He, Xiujuan Huang, Guangxian Xu, Faqing Tian, Yuanlin Ding, Wei Zhu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer
    Binhan Wang, Manni Wang, Danyi Ao, Xiawei Wei
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(5): 188799.     CrossRef
  • A novel oxidative stress- and ferroptosis-related gene prognostic signature for distinguishing cold and hot tumors in colorectal cancer
    Xu Wang, Yuanmin Xu, Longfei Dai, Zhen Yu, Ming Wang, Shixin Chan, Rui Sun, Qijun Han, Jiajie Chen, Xiaomin Zuo, Zhenglin Wang, Xianyu Hu, Yang Yang, Hu Zhao, Kongwang Hu, Huabing Zhang, Wei Chen
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer
    Mengyu Sun, Xiaoyu Ji, Meng Xie, Xiaoping Chen, Bixiang Zhang, Xiangyuan Luo, Yangyang Feng, Danfei Liu, Yijun Wang, Yiwei Li, Bifeng Liu, Limin Xia, Wenjie Huang
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment
    Shamin Azwar, Heng Fong Seow, Maha Abdullah, Mohd Faisal Jabar, Norhafizah Mohtarrudin
    Biology.2021; 10(9): 854.     CrossRef
  • CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
    Sipei Nie, Yicong Wan, Hui Wang, Jinhui Liu, Jing Yang, Rui Sun, Huangyang Meng, Xiaolin Ma, Yi Jiang, Wenjun Cheng
    Journal of Ovarian Research.2021;[Epub]     CrossRef
  • The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy
    Zeyu Wang, Yuze Liu, Yuyao Mo, Hao Zhang, Ziyu Dai, Xun Zhang, Weijie Ye, Hui Cao, Zhixiong Liu, Quan Cheng
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression
    Louis Boafo Kwantwi, Shujing Wang, Youjing Sheng, Qiang Wu
    Bioengineered.2021; 12(1): 6923.     CrossRef
  • CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities
    San-Hui Gao, Sheng-Zhi Liu, Gui-Zhen Wang, Guang-Biao Zhou
    Life.2021; 11(12): 1282.     CrossRef
  • Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment
    Margarita Neganova, Junqi Liu, Yulia Aleksandrova, Sergey Klochkov, Ruitai Fan
    Cancers.2021; 13(23): 6062.     CrossRef
  • Chemoresistance Mechanisms in Colon Cancer: Focus on Conventional Chemotherapy
    Klara Mladenić , Mirela Sedić
    Clinical Cancer Drugs.2021; 8(2): 67.     CrossRef
  • 12,082 View
  • 347 Download
  • 28 Web of Science
  • 28 Crossref
Close layer
Patient and Care Delays of Breast Cancer in China
Yue-Lin Li, Ya-Chao Qin, Lu-Ying Tang, Yu-Huang Liao, Wei Zhang, Xiao-Ming Xie, Qiang Liu, Ying Lin, Ze-Fang Ren
Cancer Res Treat. 2019;51(3):1098-1106.   Published online November 6, 2018
DOI: https://doi.org/10.4143/crt.2018.386
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study differentiates patient and care delays of breast cancer and explores the related factors as well as the associations with the prognosis in Guangzhou, a southern city of China.
Methods
A cohort of female incident breast cancer patients (n=1,551) was recruited from October 2008 to March 2012 and followed up until January 1, 2016 (n=1,374) in the affiliated hospitals of Sun Yat-sen University. The factors associated with patient and care delays were analyzed with multivariable logistic models. Cox proportional hazards regression models were constructed to estimate the impacts of the delays on the prognosis.
Results
There were 40.4% patient delay (≥3 months) and 15.5% care delay (≥1 month). The patient delay, but not the care delay, was significantly related to the clinical stage and consequently worsened the prognosis of breast cancer (hazard ratio, 1.45; 95% confidence interval, 1.09 to 1.91 for progression-free survival). The factors related to an increased patient delay included premenopausal status, history of benign breast disease, and less physical examination.
Conclusion
Patient delay was the main type of delay in Guangzhou and resulted in higher clinical stage and poor prognosis of breast cancer. Screening for breast cancer among premenopausal women may be an effective way to reduce this delay.

Citations

Citations to this article as recorded by  
  • Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain
    Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, Irene Carrasco García, Gloria Marquina, Juana María Cano Cano, Javier Martínez Trufero, Alberto Rafael Sevillano Tripero, Tania Luis García, Manuel Jorge Cuesta Rioboo, David S. Moura, Marta Renshaw, J
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Impact of the pandemic on surgical oncology in Piedmont, Italy: A retrospective observational study
    Giuseppina Lo Moro, Paolo Ragusa, Christian Previti, Alessandro Comandone, Mario Airoldi, Massimo Aglietta, Roberta Siliquini
    Journal of Surgical Oncology.2024; 129(6): 1165.     CrossRef
  • Analysis on status quo and related factors of delays in diagnosis and treatment of breast cancer in Ningxia Hui Autonomous Region
    Yuchen Wang, Zhoulan Bai, Qingyuan Liu, Hui Yu, Zhenning Tang, Xiang Liu, Qilun Liu
    Medicine.2024; 103(17): e37826.     CrossRef
  • Act or Wait? Presentation Delay in Symptomatic Breast Cancer in China
    Jinghua An, Alana D. Steffen, Eileen G. Collins, Yamilé Molina, Xiaomei Li, Carol E. Ferrans
    Cancer Nursing.2024;[Epub]     CrossRef
  • Icariside II Suppresses the Malignant Behaviors of Breast Cancer Cells by Inhibiting PTGES3 Expression
    Dongying Zhang, Shichao Zhuo, Bo Bi, Yong Liu
    Revista Brasileira de Farmacognosia.2024; 34(6): 1353.     CrossRef
  • Systems delay in women with breast cancer – A sequential explanatory mixed-methods study from central rural India
    Juhi Raut, Abhishek Joshi, Abhay Mudey
    Journal of Family Medicine and Primary Care.2024; 13(11): 5325.     CrossRef
  • Duration of the patient interval in breast cancer and factors associated with longer delays in low‐and middle‐income countries: A systematic review with meta‐analysis
    Dafina Petrova, Dunia Garrido, Zuzana Špacírová, Nicolás Francisco Fernández‐Martínez, Ganka Ivanova, Miguel Rodríguez‐Barranco, Marina Pollán, Rocío Barrios‐Rodríguez, Maria José Sánchez
    Psycho-Oncology.2023; 32(1): 13.     CrossRef
  • The Firmicutes/Bacteroidetes Ratio as a Risk Factor of Breast Cancer
    Jeongshin An, Hyungju Kwon, Young Ju Kim
    Journal of Clinical Medicine.2023; 12(6): 2216.     CrossRef
  • Delayed Presentation, Diagnosis, and Treatment of Breast Cancer Among Chinese Women
    Jinghua An, Patricia E. Hershberger, Carol Estwing Ferrans
    Cancer Nursing.2023; 46(3): 217.     CrossRef
  • Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers
    Rana Damsees, Madi Jaghbir, Mahmoud Salam, Amal Al-Omari, Nedal Al-Rawashdeh
    BMJ Open.2023; 13(5): e069529.     CrossRef
  • Predictors of Medical Care Delay or Avoidance Among Chinese Adults During the COVID-19 Pandemic
    Lili Kang, Changle Li, Huifeng Du
    Patient Preference and Adherence.2023; Volume 17: 3067.     CrossRef
  • Effects of Out-of-Hospital Continuous Nursing on Postoperative Breast Cancer Patients by Medical Big Data
    Peijuan He, Bing Zhang, Songna Shen, Kalidoss Rajakani
    Journal of Healthcare Engineering.2022; 2022: 1.     CrossRef
  • Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study
    Susanna Hilda Hutajulu, Yayi Suryo Prabandari, Bagas Suryo Bintoro, Juan Adrian Wiranata, Mentari Widiastuti, Norma Dewi Suryani, Rorenz Geraldi Saptari, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, Ibnu Purwanto, Mardiah Suci Hardianti, Matthew Joh
    PLOS ONE.2022; 17(1): e0262468.     CrossRef
  • Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway
    Danning Shi, Hongbo Li, Zeye Zhang, Yueshuang He, Meng Chen, Liping Sun, Piwen Zhao, Irina V. Lebedeva
    PLOS ONE.2022; 17(1): e0262389.     CrossRef
  • The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2−/+ Breast Cancer
    Wen Li, Qianqian Zhang, Yinlian Cai, Tingting Chen, Huaidong Cheng
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Factors Influencing Total Delay of Breast Cancer in Northeast of China
    Sihang Ren, Yuting Zhang, Pan Qin, Jia Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Patient delay to diagnosis and its predictors among colorectal cancer patients: A cross-sectional study based on the Theory of Planned Behavior
    Ying Jin, Mei-Chun Zheng, Xia Yang, Ting-Lan Chen, Jun-E Zhang
    European Journal of Oncology Nursing.2022; 60: 102174.     CrossRef
  • Research on body image cognition, social support and illness perception in breast cancer patients with different surgical methods
    Yuhan Liu, Wanli Liu, Yinglu Ma, Xiaoyue Yang, Han Zhou, Tingting Zhang, Shuhong Shao
    Frontiers in Psychology.2022;[Epub]     CrossRef
  • Delay in Seeking Medical Attention and Diagnosis in Chinese Melanoma Patients: A Cross-Sectional Study
    Xinchen Ke, Tianhao Wu, Guiyun Gao, Songchun Yang, Wenrui Lin, Yi Xiao, Minxue Shen, Mingliang Chen, Xiang Chen, Shuang Zhao, Juan Su
    International Journal of Environmental Research and Public Health.2022; 19(22): 14916.     CrossRef
  • Delay in Diagnosis and Treatment of Primary Bone Tumors during COVID-19 Pandemic in Poland
    Daniel Kotrych, Dawid Ciechanowicz, Jakub Pawlik, Martyna Szyjkowska, Bartłomiej Kwapisz, Maciej Mądry
    Cancers.2022; 14(24): 6037.     CrossRef
  • Diagnostic delay in moderately/poorly differentiated breast cancer types
    Constanze Elfgen, Sabrina Baumgartner, Zsuzsanna Varga, Kelly Reeve, Christoph J. Tausch, Vesna Bjelic-Radisic, Markus Fleisch, Uwe Güth
    European Journal of Cancer Prevention.2022; 31(2): 152.     CrossRef
  • Patients’ awareness about their own breast cancer characteristics
    Chong Geng, Guo-Jun Lu, Jing Zhu, Yu-Yang Li
    World Journal of Clinical Cases.2021; 9(24): 7043.     CrossRef
  • Delay in the diagnosis and treatment of breast cancer in Vietnam
    Sang M. Nguyen, Quang T. Nguyen, Lan M. Nguyen, Anh T. Pham, Hung N. Luu, Huong T. T. Tran, Thuan V. Tran, Xiao‐Ou Shu
    Cancer Medicine.2021; 10(21): 7683.     CrossRef
  • 9,512 View
  • 200 Download
  • 26 Web of Science
  • 23 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP